Clinical epigenomics for cardiovascular disease: Diagnostics and therapies

J Mol Cell Cardiol. 2021 May:154:97-105. doi: 10.1016/j.yjmcc.2021.01.011. Epub 2021 Feb 6.

Abstract

The study of epigenomics has advanced in recent years to span the regulation of a single genetic locus to the structure and orientation of entire chromosomes within the nucleus. In this review, we focus on the challenges and opportunities of clinical epigenomics in cardiovascular disease. As an integrator of genetic and environmental inputs, and because of advances in measurement techniques that are highly reproducible and provide sequence information, the epigenome is a rich source of potential biosignatures of cardiovascular health and disease. Most of the studies to date have focused on the latter, and herein we discuss observations on epigenomic changes in human cardiovascular disease, examining the role of protein modifiers of chromatin, noncoding RNAs and DNA modification. We provide an overview of cardiovascular epigenomics, discussing the challenges of data sovereignty, data analysis, doctor-patient ethics and innovations necessary to implement precision health.

Keywords: Arrhythmia; Cardiovascular disease; DNA methylation; Epigenetics; Precision medicine.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Biomarkers*
  • Cardiovascular Diseases / diagnosis*
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / therapy*
  • DNA Methylation
  • Disease Management
  • Disease Susceptibility
  • Epigenesis, Genetic*
  • Epigenomics* / methods
  • Gene Expression Regulation
  • Humans
  • Precision Medicine

Substances

  • Biomarkers